Latest milestone underscores accelerating regulatory momentum for the company’s lead investigational Helicon peptide, following FDA Fast Track Designation in desmoid tumors CAMBRIDGE, Mass., March 11, ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果一些您可能无法访问的结果已被隐去。
显示无法访问的结果